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Abstract
Digoxin remains one of the most frequently prescribed drugs in the management of atrial
fibrillation. The main indications for digoxin in atrial fibrillation are restoration of sinus
rhythm, prevention of recurrence and slowing of the ventricular rate. However, none of these
effects of digoxin have been confirmed in placebo controlled studies. In addition, recent reports
suggest increased mortality in patients with atrial fibrillation without heart failure taking
digoxin. The aim of this article is to review the role of digoxin in atrial fibrillation without
heart failure. (Cardiol J 2009; 16, 5: 483–486)
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Introduction
Digitalis has been used for more than two cen-
turies. Its beneficial effect in atrial fibrillation (AF)
was probably first recognized by Withering [1]: “It
(digitalis) has a power over the motion of the heart,
to a degree yet unobserved.” Indications for digi-
talis in AF without congestive heart failure are:
restoration of sinus rhythm, prevention of recur-
rence, better rate control and shorter durations of
AF paroxysms [2].
Despite these effects not being confirmed, di-
gitalis is one of the most frequently prescribed
drugs in AF [3–7]. In the SPOFITT study [7], 53%
of patients were taking digoxin (D). Furthermore,
D is considered a relatively safe drug despite its nar-
row therapeutic toxic ratio. This assumption, how-
ever, was recently challenged by reports suggest-
ing that D has adverse effects on survival in patients
with higher than 1.2 ng/mL serum D concentration
(SDC) [6] and in those with AF without heart fail-
ure [6–10]. The aim of this review is to discuss the
role of D in AF in patients with preserved left ven-
tricular function.
Electrophysiological effect
of digoxin on the atria
Digitalis, similarly to AF, shortens the atrial
effective refractory period (ERP) also known as
electrical remodeling [11–16]. In an experimental
model of AF, delayed recovery of atrial electric re-
modeling after D was reported by Tieleman et al. [13]
while Sticherling et al. [14] found similar results in
humans. According to these authors [14], shorten-
ing of atrial ERP was more pronounced with se-
condary episodes of AF more common in digitalized
patients compared to controls. Furthermore, Tiele-
man et al. [15] reported a higher, though not statis-
tically significant, incidence of recurrence of AF
after cardioversion in patients taking D. This sug-
gests that D is associated with a higher rate of re-
currence of AF and could be the first step in the
development of chronic AF [11, 16].
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Role of digitalis in
restoration of sinus rhythm
Until a few decades ago, the role of digitalis in
AF was mostly based on clinical experience and
some experimental results. Friedberg [17] suggest-
ed that conversion of AF by digitalis is “purely co-
incidental.” Pick [18] believed that D has an an-
tiarrhythmic effect in AF. According to Hurst [19],
improved hemodynamics and ventricular rate slow-
ing are the most likely mechanisms for restoration
of sinus rhythm. Finally, according to Schamroth
[20], digitalis has a pro-fibrillatory effect.
Weiner et al. [21] evaluated the effect of D on
conversion of new onset AF (< 14 days) for 47 epi-
sodes in 45 patients. Patients received 1.5 mg of D
intravenously over 12 hours and were followed up
to 96 hours. Sinus rhythm was restored in 85% of
AF episodes. The main limitations of Weiner’s re-
port are the lack of a control group and concomi-
tant use of additional drugs. In addition to lone AF,
patients included in this study had ischemic heart
disease, hypertension and valvular heart disease.
Falk et al. [3] reported the first placebo con-
trol study in 36 patients with AF < 7 days without
heart failure, acute ischemic process, electrolyte
imbalance or severe renal impairment. Digoxin was
administered orally 1.4 mg in divided doses at
0, 4, 8 and 14 hours, respectively, or until conver-
sion. Restoration of sinus rhythm occurred in eight
patients (44%) in the placebo group and in nine
(50%) patients taking D. There was no significant
difference between the two groups.
Jordaens et al. [4] reported similar results ten
years later. These authors administered 1.25 mg of D
over the course of eight hours to 19 patients, while
20 patients received a placebo. The two groups
were matched for age, gender, body weight, under-
lying heart disease, initial heart rate and duration
of AF. Digoxin and placebo restored sinus rhythm
within 12 hours in 43.6% and 47.4%, respectively,
without significant difference in the ventricular rate
before or after cardioversion.
In the DAAF trial [5], 239 patients with recent
onset AF were divided into two groups: 122 re-
ceived a placebo and 117 D. The average D dose
was 0.88 mg. Restoration of sinus rhythm in the D
and placebo group was 51% and 46% respectively
(not significant).
The main difference between the DAAF and
the two previous studies was the D effect on ven-
tricular rate. In the DAAF study, D users had sig-
nificantly slower ventricular rate as early as two
hours after initiation of therapy, persisting up to
16 hours. The reason for different D effect on ven-
tricular rate is not clear. One possible explanation
is the role of the autonomic nervous system. For
example, in patients with high sympathetic tone at
the onset of AF, D may be less effective in control-
ling the ventricular rate [22].
Finally, Murgatroyd et al. [23] reported a double
blind placebo controlled study of D’s effect in patients
with paroxysmal AF. The end point was time interval
to two symptomatic episodes of AF, using the patient’s
activated event recorder. There were 43 patients
divided into two groups. The median time interval
before two transmitted AF episodes in the D and
control group was 18.7 days and 13.5 days respec-
tively (p < 0.05). Time to the first episode of symp-
tomatic AF was also longer in D users. As in the
DAAF study [5], the heart rate was lower in patients
taking D (128 bpm) than in the control group (138 bpm;
p < 0.01). As the authors pointed out, the most likely
reason for the delay of symptomatic AF was slower
rate rather than restoration of sinus rhythm.
Adverse effects of digoxin
Increased mortality in patients after acute
myocardial infarction taking D was suggested in the
early 1980s based on post hoc analysis [24, 25].
More recently, Spargias et al. [26] found D as an
independent predictor of increased total mortality
(hazard ratio of 1.41 and p = 0.014) in patients with
heart failure after myocardial infarction.
Similarly, in the DIG [27] patients taking D had
a higher cardiac death rate in comparison to those
in the placebo group (p = 0.04). According to Gheor-
ghiade and Pitt [28], cardiac arrhythmias without
worsening heart failure and coronary artery disease
are probably the main causes of increased cardiac
mortality in the DIG study.
Higher mortality of subjects taking D was also
reported by Casiglia et al. [10] in a population study
of 2,254 patients aged over 65. The patients includ-
ed in this study were followed for 12 years and
divided into two groups. In the first group were
1,977 patients in sinus rhythm without heart fail-
ure. In the second were 187 patients with heart fail-
ure and 90 patients with AF.
Patients in the first group who were taking D
had a higher 12-year mortality than untreated ones
(58% vs. 49.5%; p < 0.0001). The cardiovascular
mortality was also higher in patients taking D (21.5%
vs. 17.7%; p < 0.0001). In patients with heart fail-
ure, the survival rate was similar in both groups, and
in those with AF, mortality due to heart failure was
higher in patients taking D (28.1 vs. 4.2%; p = 0.02).
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The adverse effect of D is also seen in patients
with AF. In the AFFIRM sub-study [8], patients
taking D had a higher mortality than non-digitalized
ones (hazard ratio 1.42). According to the authors,
the lower survival rate in patients taking D was
more likely due to an increased risk of death, rath-
er than an adverse D effect [8]. However, the au-
thors also suggested that “there may be other meas-
ured or unmeasured variables that influence physi-
cians to choose digoxin.”
Hallberg et al. [9] compared one-year mortali-
ty in three groups of patients after discharge from
coronary care units in Sweden. In the first group
were patients with AF without heart failure; the
second were those with congestive heart failure;
and the third group were patients with AF and con-
gestive heart failure.
The main finding of Hallberg’s study was in-
creased mortality in D users without heart failure
(hazard ratio 1.42). No adverse effect of D was seen
in patients with or without AF and heart failure.
Among important limitations of this study were:
SDC was not available, probably not all confounders
could be included, and there was no information on
renal and left ventricular function. Probably more
important was the post-discharge management. For
example, did all patients continue to take D, how
many were treated with beta-blockers, antiarrhyth-
mic drugs and what was the rate of sinus rhythm
restoration?
Gjesdal et al. [7] analyzed mortality of D users
and non-users in the SPORTIF III and V study,
which compared warfarin with a direct thrombin
inhibitor ximelagatran. In this report, of 7,329 pa-
tients, 53.4% were taking D. The mortality was
6.5% in D users and 4.1% in non-users (p < 0.001;
hazard ratio of 1.58).
After risk factor adjustment, increased mortali-
ty was still significantly higher in digitalized patients
(p < 0.001; hazard ratio 1.53). Patients taking D had
a higher incidence of fatal myocardial infarction (8.6%
vs. 5.7%; p = 0.026), sudden cardiac death and heart
failure. Despite being a planned sub-study before its
closure, this study has certain limitations. Most likely
some confounded risk factors could not be included
in the analysis. Also, the indications for D, mecha-
nism of heart failure and SDC were unknown.
What are the possible explanations for in-
creased mortality in patients with AF taking D? One
explanation is that D has a narrow therapeutic/
/toxic ratio. Therefore a pro-arrhythmic effect has
to be considered. This, however, seems unlikely
because digitalis toxicity usually causes symptoms,
and patients included in studies are closely followed.
A second explanation is that digitalized patients
have a higher incidence of fatal myocardial infarction
and ’other vascular death’ suggesting intravascular
thrombosis as the cause of increased mortality. This
explanation is supported by recent studies, accord-
ing to which not only AF but also D induces plate-
lets’ and endothelial cells’ activation [28, 29]. The
role of platelets and endothelial cell activation in in-
travascular thrombosis is well known.
Finally, it is important to point out that the
adverse effects of D are based on univariate and
multivariate analysis and/or on retrospective stud-
ies instead of prospective randomized ones. Be-
cause of a lack of commercial support, a randomized
study confirming adverse D is unlikely.
An alternative practical approach is to replace
D with more effective pharmacological and non-
-pharmacological therapies such as electric cardio-
version, ibutilide or pill in the pocket (flecainide or
propafenone). To achieve these goals, the medical
community has to become more familiar, not only
with the limited efficacy of D in AF without heart
failure, but also with its possible adverse effects.
Conclusions
We reviewed the role of D in patients with AF
without congestive heart failure. According to pla-
cebo controlled studies, D has no role in cardiover-
sion or recurrence prevention of AF. The efficacy
of D in patients with paroxysmal AF as an atrio-
ventricular nodal blocking agent is not completely
clear. Some studies suggest better ventricular rate
control, others failed to confirm atrioventricular
nodal blocking D effect.
An important recent finding is the adverse ef-
fect of D in patients with AF and normal left ven-
tricular function. The best approach to confirm this
unfavorable D effect on survival would be a rand-
omized study. As we have said, this is unlikely due
to a lack of commercial support. We believe that for
patients with AF and normal left ventricular func-
tion, the best practical recommendation is to replace
D with more effective therapies for cardioversion
and prevention of recurrence and rate control.
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